High response rates reported by GSK and iTeos at the 2024 European Society for Medical Oncology Congress offer a ray of light ...

The published belrestotug/dostarlimab data is still too immature to prove the combination’s capability to disrupt the NSCLC ...

The results of the GALAXIES Lung-02 study reported at the ESMO congress in Barcelona showed that the drug – added to GSK's PD ...

The European Society for Medical Oncology’s annual meeting this week featured the hottest emergent areas of cancer ...

Teos Therapeutics' belrestotug shows promising response rates in lung cancer trials. Read more to see why I'm bullish on ITOS ...

The combination of belrestotug and dostarlimab significantly improved response rates in patients with previously untreated ...

According to Biospace.com "The solid tumors market size reached a value of US$ 170.3 Billion in 2023. Looking forward, the market is expected to reach US$ 375.4 Billion by 2034, exhibiting a growth ...

Recently the FDA approved a new immunotherapy medication, Jemperli, which “dramatically changed the landscape for women with endometrial cancer,” Lewin says. It’s been almost four years ...

AstraZeneca (Nasdaq: AZN) Roche (OTCQX: RHHBY) September 17, 2024 - Investorideas , a go-to investing platform, releases the first of a two-part series looking at news and developments for the ...

All three were in study arms involving ITeos’ drug; none of the 32 trial participants given only GSK’s therapy, Jemperli, died from treatment-related side effects. This kind of inflammatory reaction ...